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Abstract
Endosialin/TEM1/CD248 is a cell surface protein expressed at high levels by the malignant cells of about 50% of sarcomas and neuroblastomas. The antibody-drug conjugate Ewing's sarcoma lines were selected for in vivo efficacy testing of the anti-endosialin-MC-VC-PABC-MMAE conjugate. The treatment groups included a vehicle control, unconjugated antiendosialin, an admix control consisting of anti-endosialin and a dose of free MMAE equivalent to the dose administered as the ADC, and the anti-endosialin-MC-VC-PABC-MMAE conjugate.
The unconjugated anti-endosialin had no antitumor activity and resulted in similar tumor growth as the vehicle control. The admix control produced a modest tumor growth delay. Administration of the anti-endosialin-MC-VC-PABC-MMAE conjugate resulted in a marked prolonged tumor response of both xenograts. These proof-of-concept results break new ground and open a promising drug discovery approach to these rare and neglected tumors.
INTRODUCTION
Endosialin/CD248/TEM1, a transmembrane glycoprotein expressed on pericytes and fibroblasts during tissue development and present in the adult in several mesenchymal cell types, is associated with tumor neovascularization and inflammation and has emerged as a molecular marker and therapeutic target for sarcoma (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . First recognized as the antigen of an antibody raised in mice against human fetal fibroblasts (FB5), endosialin was found to be expressed by human solid tumor vasculature (13) and was detected in a subset of cells enriched for endothelium via selection with P1H12, an anti-CD146 antibody, from a colorectal tumor specimen (14) . Endosialin expression in tumor vasculature occurs mainly in pericytes and stromal fibroblasts (15) (16) (17) .
In mouse embryos, endosialin/TEM1-lacZ co-localizes with most vimentin-positive cells and a large portion of CD31-or desmin-positive cells. In the mouse, endosialin is expressed throughout embryonic and adult development in mesenchymal cells related to blood vessels (18) . Endosialin (12) . A retrospective analysis of diagnostic reports showed that endosialin can be detected in high-grade disease and metastasis. In disseminated human sarcoma xenografts, endosialin protein expression was maintained at different anatomic sites (7) (8) (9) ). An anti-endosialin MORAb-004, which is a humanized FB5 antibody, has completed An anti-endosialin-MC-VC-PABC-monomethyl auristatin E ADC was prepared and assessed in cell culture and in two human tumor xenograft models, demonstrating high specificity and profound, durable antitumor efficacy. 
MATERIALS AND METHODS
Anti-endosialin-MC-VC-PABC-monomethylauristatin E. The fully human antiendosialin antibody was generated through a partnership with Kyowa Hakko Kirin Co., Ltd, Takasaki, Japan, as described previously (12) . Synthetic procedures for the conjugation of the linker-functionalized monomethylauristatin E (MMAE) to anti-endosialin were performed as detailed in the following published procedure reports (35, 36) . Briefly, anti-endosialin-MC-VC-PABC-MMAE was prepared by partial reduction of the antibody interchain disulfides with 3. Excess small molecule was removed using QuadraPure™ DET (Sigma-Aldrich Co., St. Louis, MO) polystyrene scavenging beads. Yields were 85-95% based upon protein recovery.
The drug/antibody ratio (DAR) was determined by C8 reversed-phase LC/MS following published procedures (35, 36) . The ADC was deglycosylated with PNGase F overnight at 37°C, dialyzed to remove salt, and reduced to smaller fragments (light and heavy chains) using 20 mM dithiothreitol (DTT) for 30 min at 37°C. Aliquots were injected in the LC/MS instrument and electrospray ionization mass spectra of light and heavy chains were recorded and deconvoluted, revealing conjugation profiles that included free, mono-, di-, and tri-conjugated species. The integrated peak areas were then used to determine the weighted average ratios for light and heavy chains. The DAR was determined by doubling and adding the light and heavy chains ratios. The 
untreated control for each cell line, and IC 50 values were determined from the graphical data.
Each cell line was tested in at least two independent experiments.
Immunohistochemistry. Immunohistochemistry was performed as described previously (12) . The function of endosialin remains largely unknown and it appears to be expressed at relatively high levels by about 50% of sarcomas. The implication is that endosialin is not essential for cell viability or proliferation. The requirements for an ADC target include being expressed on the cell surface and that an antibody to the extracellular domain of the target protein be internalized into the cell along with the target protein to enable delivery of the cytotoxic drug pay-load. Some ADC targets such as CD30 occur at high levels on the cell surface of specific diseases, anaplastic large cell lymphoma and Hodgkin lymphoma with sufficient frequency that diagnostic testing for the target is not essential. Brentuximab vedotin (SGN-35) reached FDA approval in 2011 for treatment of refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma without the requirement for testing tumor cells for the CD30 (47) . Given the variability of endosialin expression across tumors and within tumors (7-9, 12), detection of endosialin protein using the immunohistochemical assay previously described (12) and used herein should be a key component of any endosialin-directed therapy as a companion diagnostic to select potential responders.
In vivo xenografts.
This present proof-of-concept study demonstrates that endosialin-positive tumors can be specifically and effectively targeted by a monoclonal anti-endosialin antibody conjugated to the potent cytotoxic small molecule MMAE. The response is complete and durable, warranting extensive preclinical evaluation of endosialin-directed ADCs in endosialin-positive disease.
Anti-endosialin-MMAE brings the promise of personalized medicine to sarcoma and neuroblastoma patients. Treatments were administered by intravenous injection 3-times per week for 2 weeks. The data are the means +/-SD for groups of 9 mice. B. Survival of female nude mice bearing
